Skip to main content
International Journal of Medical Sciences logoLink to International Journal of Medical Sciences
. 2021 Jan 1;18(2):528–533. doi: 10.7150/ijms.50966

Prevalence and prognosis of synchronous distant metastatic tonsil squamous cell carcinomas

Yujiao Li 1,2, Chaosu Hu 1,2,
PMCID: PMC7757145  PMID: 33390822

Abstract

Background: To analyze the prevalence proportions and prognostic factors of synchronous distant metastases in patients with tonsil squamous cell carcinomas (TSCC).

Methods: TSCC patients were extracted from the Surveillance, Epidemiology and End Results (SEER) database between 2010 and 2014. We examined the association between clinical manifestations and distant metastases using Chi-squared tests. Predictors of 5-year survival were assessed using univariate and multivariate analyses.

Results: A total of 6193 patients were analyzed and lung was the most common site of distant metastases. Poorly/undifferentiated differentiation was found to be significantly correlated with lung metastasis (p=0.033) and liver and bone metastases were associated with African American (p=0.000 and p=0.000, respectively). A higher T classification was associated with higher prevalence of lung, liver, bone and brain metastasis (p=0.000, p=0.000, p=0.000 and p=0.007, respectively). The same results were found in N classification in lung, liver, and bone metastasis (p=0.000, p=0.000, and p=0.000, respectively). Worse prognosis was associated with older age, Blacks, lower grade, higher T and N classification, no surgery therapy and more metastatic sites.

Conclusion: Lung was the most frequent lesion of synchronous distant metastases and liver and bone metastases were associated with African American. Higher T and N classification were independent prognostic parameters for higher prevalence of lung, bone, liver and brain metastasis. Worse prognosis was associated with older age, African Americans, lower grade, higher T and N classification, no surgery therapy and more metastatic sites.

Keywords: synchronous distant metastases, tonsil squamous cell carcinomas, metastatic pattern, prevalence, prognosis

Introduction

Tonsil squamous cell carcinoma (TSCC) is one of the most common oropharyngeal neoplasm and the incidence rates of TSCC have significantly increased in recent decades 1-3. Several studies have described the association between the clinicopathological characteristics, including age, tumor size, tumor grade, tumor stages at presentation, and lymph node or distant metastases and clinical outcomes of TSCC. Up-front surgery followed by adjuvant therapy, if appropriate, or radiotherapy alone has been the principal treatment modality for early-stage TSCC and postoperative radiotherapy has been used for close or positive resection margins, T3-4 tumors, and neck node metastases 4.

Metastases are the main cause of human cancer deaths, and its treatment continues to be a major challenge. The identification of factors associated with distant metastases is of paramount relevance for therapeutic planning. Our goals were to analyze the prevalence proportions and prognosis of synchronous distant metastases in patients with TSCC using the Surveillance, Epidemiology, and End Results (SEER) database.

Materials and Methods

Cohort population

We obtained data from the current SEER database, which consists of 18 population-based cancer registries. This database collects and publishes cancer prevalence and survival data covering approximately 28% of the total population in the United States. SEER*Stat Version 8.3.4 (http://www. seer.cancer.gov/seerstat) from the National Cancer Institute was used to identify eligible patients in this study. Because the SEER database began collecting information on the presence or absence of metastases at the time of diagnosis in 2010, we included patients diagnosed with microscopically confirmed TSCC between 1 January 2010 and 31 December 2014. We selected patients with only one primary malignancy in their lifetime. We excluded patients mainly because of lack of pathology type of tumor, unknown racial information, unstaged tumors or 'blanks' metastatic site. In total, 6193 TSCC patients were eligible for inclusion in the prevalence analyses.

Statistical analysis

Descriptive statistics were used to examine the baseline characteristics of the patients. The primary study outcomes were overall survival (OS) and cancer-specific survival (CSS). OS was defined as time to the date of death due to any cause or the date of last follow-up. CSS was defined as time from initial treatment to death due to cancer. Kaplan-Meier survival curves were compared using the log-rank test. Hazard analysis was conducted using the Cox proportional hazards model. SPSS software, version 22.0 (SPSS, Chicago, IL, USA) was used for additional data processing. A probability value (p value) of < 0.05 was considered statistically significant for all tests.

Results

Clinical Characteristics of all patients

Data for a total of 6193 patients, including 5083 males and 1110 females, were investigated. The median age was 59 months (range, 17-99 months). Among the cohort of the patients, 4.4%, 40.6% and 55.0% tumors were well differentiated (Grade I), moderately differentiated (Grade II) and poorly/undifferentiated differentiated (Grade III), respectively. About 63.8% of the patients were stage IV (Figure 1).

Figure 1.

Figure 1

Distribution of tumor stages.

According to the 7th edition of UICC/AJCC Staging System, 1835 patients (29.6%) were T1, 2484 patients (40.1%) were T2, 1023 patients (16.5%) were T3, 566 patients (9.1%) were T4a, and 285 patients (4.6%) were T4b. With regard to N classifications, 1259 patients (20.3%) were N0, 1296 patients (20.9%) were N1, 719 patients (11.6%) were N2a, 2087 patients (33.7%) were N2b, 555 patients (9.0%) were N2c, and 277 patients (4.5%) were N3. Patients' characteristics are listed in Table 1.

Table 1.

Clinical manifestations of 6193 patients

Number of patients %
Age
Median 59
Range 17-99
Gender
Male 5083 82.1
Female 1110 17.9
Race
Caucasian 5447 88.0
Asian 221 3.6
African American 525 8.5
T classification
T1 1835 29.6
T2 2484 40.1
T3 1023 16.5
T4a 566 9.1
T4b 285 4.6
N classification
N0 1259 20.3
N1 1296 20.9
N2a 719 11.6
N2b 2087 33.7
N2c 555 9.0
N3 277 4.5
Grade
1 272 4.4
2 2512 40.6
3 3409 55.0
Surgery therapy
Yes 3401 54.9
No 2792 45.1
Tumor location
Tonsillar fossa 770 12.4
Tonsillar pillar 380 6.1
Overlapping lesion of tonsil 61 1.0
Tonsil, NOS 4982 80.4
Metastasis patterns
No metastasis site 6091 98.4
One metastasis site 83 1.3
Multiple metastasis sites 3 0.3

Abbreviations: NOS: not otherwise specified.

Metastasis pattern

At the time of diagnosis, there were 17 patients with liver metastasis, 67 patients with lung metastasis, 37 patients with bone metastasis and 6 patients with brain metastasis.

As shown in Table 2, tumor grade was found to be significantly correlated with lung metastasis and poorly/undifferentiated differentiation was an independent prognostic parameter for higher prevalence of lung metastasis (p=0.033). What's more, we observed that T classification was also an independent parameter for metastatic diseases. A higher T classification was associated with higher prevalence of lung, bone, liver and brain metastasis (p=0.000, p=0.000, p=0.000 and p=0.007, respectively). The same results were found in N classification in lung, bone, and liver metastasis (p=0.000, p=0.000, and p=0.000, respectively). In addition, liver and bone metastases were associated with African American (p=0.000 and p=0.000, respectively).

Table 2.

Demographic characteristics of patients with and without metastases

Features Lung Metastasis P
value
Liver Metastasis P
value
Bone Metastasis P
value
Brain Metastasis P
value
No Yes No Yes No Yes No Yes
Gender 0.076 0.021 0.081 0.294
Male 5034 49 5073 10 5057 26 5079 4
Female 1092 18 1103 7 1099 11 1108 2
Age 0.462 0.149 0.248 0.426
≤59 3274 39 3307 6 3297 16 3311 2
>59 2852 28 2869 11 2859 21 2876 4
Race 0.143 0.000 0.000 0.086
Caucasian 5393 54 5436 11 5424 23 5443 4
Asian 218 3 221 0 219 2 221 0
African American 515 10 519 6 513 12 523 2
Grade 0.033 0.184 0.360 0.783
1 272 0 272 0 272 0 272 0
2 2476 36 2508 4 2498 14 2510 2
3 3378 31 3396 13 3386 23 3405 4
T classification 0.000 0.000 0.000 0.007
T1 1826 9 1833 2 1829 6 1835 0
T2 2470 14 2480 4 2470 14 2481 3
T3 1006 17 1021 2 1019 4 1023 0
T4a 548 18 558 8 557 9 563 3
T4b 276 9 284 1 281 4 285 0
N classification 0.000 0.000 0.000 0.527
N0 1256 3 1258 1 1253 6 1257 2
N1 1288 8 1293 3 1292 4 1295 1
N2a 716 3 719 0 718 1 719 0
N2b 2069 18 2083 4 2078 9 2086 1
N2c 529 26 549 6 542 13 554 1
N3 268 9 274 3 273 4 276 1
Tumor location 0.937 0.130 0.033 0.712
Tonsillar fossa 763 7 769 1 767 3 769 1
Tonsillar pillar 376 4 378 2 379 1 379 1
Overlapping lesion of tonsil 60 1 60 1 59 2 61 0
Tonsil, NOS 4927 55 4969 13 4951 31 4978 4

Abbreviations: NOS: not otherwise specified.

Survival

The overall mean follow-up of all patients in the cohort was 21.0 months (range, 0-59 months). In the univariate analysis, age, gender, race, grade, primary site, T category, N category, distant metastases and surgery therapy were significantly associated with OS and CSS (P < 0.05).

Gender, age, race, grade, primary site, T classification, N classification, history of surgery and distant metastases were selected in the multivariate model. Age, race, grade, primary site, T classification, N classification, surgery therapy and distant metastases were all independent prognostic factors in the multivariable analysis for CSS (Table 3). Elderly black patients with higher T or N classification, multiple sites of metastases and no surgical therapy to primary tumor were more likely to reduce life expectancy.

Table 3.

Multivariable logistic regression for OS and CSS of TSCC in the SEER cohort

Prognostic factor Overall survival Cancer-specific survival
P value HR Lower CI Higher CI P value HR Lower CI Higher CI
Age 0.000 1.843 1.625 2.090 0.000 1.738 1.477 2.046
Gender 0.344 0.251
Male 1 (reference) 1 (reference)
Female 1.054 0.904 1.229 1.094 0.893 1.341
Race 0.000 0.000
Caucasian 1 (reference) 1 (reference)
Asian 1.231 0.894 1.694 1.256 0.847 1.860
African American 1.694 1.432 2.003 1.663 1.328 2.082
Grade 0.000 0.000
1 1 (reference) 1 (reference)
2 0.789 0.610 1.020 0.649 0.454 0.927
3 0.575 0.443 0.746 0.439 0.306 0.629
T classification 0.000 0.000
T1 1 (reference) 1 (reference)
T2 1.172 0.971 1.415 1.192 0.914 1.555
T3 1.753 1.422 2.161 1.860 1.397 2.476
T4a 2.591 2.084 3.220 3.032 2.257 4.072
T4b 3.181 2.471 4.094 3.563 2.557 4.964
N classification 0.285 0.000
N0 1 (reference) 1 (reference)
N1 0.843 0.696 1.021 1.228 0.926 1.628
N2a 0.684 0.519 0.901 0.838 0.562 1.248
N2b 0.828 0.697 0.984 1.167 0.903 1.508
N2c 1.121 0.907 1.386 1.613 1.208 2.154
N3 1.229 0.935 1.615 2.004 1.421 2.826
Tumor location 0.000 0.003
Tonsillar fossa 1 (reference) 1 (reference)
Tonsillar pillar 1.145 0.889 1.474 1.100 0.784 1.544
Overlapping lesion of tonsil 0.964 0.568 1.636 0.823 0.414 1.636
Tonsil, NOS 0.819 0.695 0.965 0.790 0.635 0.982
Surgery therapy 0.000 1.890 1.636 2.183 0.000 2.276 1.859 2.788
Distant metastases 0.000 0.000
No 1 (reference) 1 (reference)
Single 3.790 2.821 5.093 4.972 3.586 6.893
Multiple 8.192 4.844 13.854 12.145 6.799 21.695

Abbreviations: CI, confidence interval; HR, hazard ratio; P values were calculated using an adjusted Cox proportional-hazards model; NOS, not otherwise specified.

As shown in Figure 2, 5-year CSS are 93.6% and 84.5% for localized and regional TSCC patients, respectively, which are much higher than metastatic TSCC patients (62.6%). The same results were found in OS.

Figure 2.

Figure 2

Kaplan-Meier analysis of overall survival and cancer-specific survival in localized, regional and metastatic tonsil squamous cell carcinomas patients. A, overall survival in localized, regional and metastatic tonsil squamous cell carcinomas patients (P < 0.05). B, cancer-specific survival in localized, regional and metastatic tonsil squamous cell carcinomas patients (P < 0.05).

Discussion

In this study, 6193 patients with TSCC were evaluated and 86 (0.13%) patients had synchronous distant metastases at diagnosis. In the present series, the niches of distant metastasis were predominantly located in the lungs, bones, liver and brain, in accordance with the literature 5. We observed some interesting relationships between the clinicopathological characteristics and distant metastases patterns. For instance, liver and bone metastases were associated with African American. Nabil et al. found that TSCC in white men is likely human papillomavirus (HPV) driven, and Frederic et al. found that HPV-negativity are factors associated with the development of distant metastases, which could partly explain the observed ethnic-based differences 6, 7. However, absence of information about HPV and/or p16 status of the patients in the current analysis prevented us to adjust our analyses for these important factors. What's more, advanced T classifications increased the risk of distant metastases and advanced regional disease (N2 or N3 disease) are found in patients with M1 disease, which were consistent with many other studies 7-10.

A number of variables influencing the prognosis of TSCC have been described previously (Table 3). In the present study, eight clinicopathological factors were found to be associated with patient OS by univariate analysis, including age, race, grade, primary site, T classification, N classification, distant metastases and surgery therapies. Based on the present study, Caucasian was associated with a better prognosis than Asian and African American. In terms of age, several reports have shown that patients' age is one of the prognostic factors in oropharyngeal carcinoma including TSCC 11, 12. The differential protective effect of marriage based on HPV infection, which correlated with favorable prognosis, was more frequently observed in younger Caucasian patients than in the elderly 13; therefore, old aged African American could be secondary surrogates of poor tumor biology which is unrelated to HPV infection. Unfortunately, because the HPV and/or p16 status of patients in the present study was unknown, this hypothesis could not be tested. Regarding that many recent studies for altering therapy based on HPV status are in progress, the lack of details of HPV status in this study has significant limitations 14.

Furthermore, early diagnosis and treatment are particularly important; especially the incidence of TSCC has increased in past 3 decades 2, 3, 15, 16. We observed that 5-year CSS are 93.6% and 84.5% for localized and regional TSCC patients, respectively, which are much higher than metastatic TSCC patients(62.6%). we observed the same pattern of associations for OS (Figure 2).

This is the first population-based analysis assessing prevalence proportion and prognostic factors of distant metastases of TSCC patients. Some limitations of our study should be acknowledged. First of all, the SEER database only provides information about four sites of metastases at diagnosis: bone, brain, lung, and liver. We don't have information of metastasis to other sites, which may influence the prognostic assessment of the metastases group. Second, the lack of data on additional predictors of OS such as HPV and/or p16 status, performance status, comorbidities, chemotherapy and/or postoperative radiotherapy, positive surgical margins at final pathology prevented us to adjust our analyses for these important factors.

Conclusion

Lung was the most frequent lesion of synchronous distant metastases and liver and bone metastases were associated with African American. Higher T and N classification were independent prognostic parameters for higher prevalence of lung, bone, liver and brain metastasis. Worse prognosis was associated with older age, African Americans, lower grade, higher T and N classification, no surgery therapy and more metastatic sites.

Acknowledgments

We acknowledge the support of the Department of Radiation Oncology, Fudan University Shanghai Cancer Center. The views expressed in this publication are those of the authors.

Ethical Approval and Informed Consent

All procedures performed in studies involving human participants were in accordance with the ethical standards of Fudan University Shanghai Cancer Center Ethics committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The experimental protocols were also approved by Fudan University Shanghai Cancer Center Ethics committee. Written informed consent was obtained from all individual participants included in the study.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Funding

The study was funded by the National Key Technologies Research and Development Program on Prevention and Control of Chronic Non-communicable Diseases (Grant No. 2018YFC1313204).

Author Contributions

Yujiao Li and Chaosu Hu have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

References

  • 1.Ryerson AB, Peters ES, Coughlin SS. et al. Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. CANCER-AM CANCER SOC. 2008;113(10 Suppl):2901–2909. doi: 10.1002/cncr.23745. [DOI] [PubMed] [Google Scholar]
  • 2.Schantz SP, Yu GP. Head and neck cancer incidence trends in young Americans, 1973-1997, with a special analysis for tongue cancer. Arch Otolaryngol Head Neck Surg. 2002;128(3):268–274. doi: 10.1001/archotol.128.3.268. [DOI] [PubMed] [Google Scholar]
  • 3.Shiboski CH, Schmidt BL, Jordan RCK. Tongue and tonsil carcinoma: Increasing Trends in the U.S. Population Ages 20-44 Years. CANCER-AM CANCER SOC. 2005;103(9):1843–1849. doi: 10.1002/cncr.20998. [DOI] [PubMed] [Google Scholar]
  • 4.Forastiere A, Goepfert H, Goffinet D. et al. NCCN practice guidelines for head and neck cancer. National Comprehensive Cancer Network. Oncology (Williston Park) 1998;12(7A):39–147. [PubMed] [Google Scholar]
  • 5.Sacks R, Law JY, Zhu H. et al. Unique patterns of distant metastases in HPV-Positive head and neck cancer. Oncology. 2020;98(3):179–185. doi: 10.1159/000504651. [DOI] [PubMed] [Google Scholar]
  • 6.Saba NF, Goodman M, Ward K. et al. Gender and ethnic disparities in incidence and survival of squamous cell carcinoma of the oral tongue, base of tongue, and tonsils: A surveillance, epidemiology and end results Program-Based analysis. Oncology. 2011;81(1):12–20. doi: 10.1159/000330807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Duprez F, Berwouts D, De Neve W. et al. Distant metastases in head and neck cancer. Head Neck. 2017;39(9):1733–1743. doi: 10.1002/hed.24687. [DOI] [PubMed] [Google Scholar]
  • 8.Weller MA, Ward MC, Berriochoa C. et al. Predictors of distant metastasis in human papillomavirus-associated oropharyngeal cancer. Head Neck. 2017;39(5):940–946. doi: 10.1002/hed.24711. [DOI] [PubMed] [Google Scholar]
  • 9.Ferlito A, Shaha AR, Silver CE. et al. Incidence and sites of distant metastases from head and neck cancer. O.R.L. Journal for oto-rhino-laryngology and its related specialties. 2001;63(4):202–207. doi: 10.1159/000055740. [DOI] [PubMed] [Google Scholar]
  • 10.Uhliarová B, Švec M. Incidence and risk factors of distant metastases of head and neck carcinoma. Klinicka Onkologie. 2019;32(4):294–299. doi: 10.14735/amko2019294. [DOI] [PubMed] [Google Scholar]
  • 11.Song S, Wu H, Lee CG, Chemoradiotherapy versus surgery followed by postoperative radiotherapy in tonsil cancer: Korean Radiation Oncology Group (KROG) study. BMC CANCER. 2017. 17(1) [DOI] [PMC free article] [PubMed]
  • 12.Koo TR, Wu H, Hah JH. et al. Definitive Radiotherapy versus Postoperative Radiotherapy for Tonsil Cancer. CANCER RES TREAT. 2012;44(4):227–234. doi: 10.4143/crt.2012.44.4.227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Westra WH. The changing face of head and neck cancer in the 21st century: The impact of HPV on the epidemiology and pathology of oral cancer. Head Neck Pathol. 2009;3(1):78–81. doi: 10.1007/s12105-009-0100-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Vokes EE, Agrawal N, Seiwert TY. HPV-Associated head and neck cancer. J Natl Cancer Inst. 2015;107(12):v344. doi: 10.1093/jnci/djv344. [DOI] [PubMed] [Google Scholar]
  • 15.Reddy VM, Cundall-Curry D, Bridger M. Trends in the incidence rates of tonsil and base of tongue cancer in England, 1985-2006. The Annals of The Royal College of Surgeons of England. 2010;92(8):655–659. doi: 10.1308/003588410X12699663904871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Olaleye O, Moorthy R, Lyne O. et al. A 20-year retrospective study of tonsil cancer incidence and survival trends in South East England: 1987-2006. CLIN OTOLARYNGOL. 2011;36(4):325–335. doi: 10.1111/j.1749-4486.2011.02361.x. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.


Articles from International Journal of Medical Sciences are provided here courtesy of Ivyspring International Publisher

RESOURCES